A dual GIP/GLP-1 receptor agonist examined in human metabolic studies.
In simple words
Tirzepatide is a peptide that acts on GIP and GLP-1 receptors, which respond to gut-hormone signals. Human studies examine body-weight and metabolic responses in defined study populations.
The named research compound is described here; the identity and formulation of this catalogue vial have not been independently verified.
Evidence on studied compounds does not establish the identity, purity, safety, or regulatory approval of the catalogue vial. No Canadian regulatory status is assessed here.
Research questions about Tirzepatide
What is Tirzepatide?
Tirzepatide is a peptide that acts on GIP and GLP-1 receptors, which respond to gut-hormone signals. Human studies examine body-weight and metabolic responses in defined study populations.
What types of research are cited for Tirzepatide?
The Tirzepatide profile contains the following selected evidence. This is not a systematic review or a complete inventory of research.
Tirzepatide: SURMOUNT-1 (2022): Human — randomized phase 3 trial
The named research compound is described here; the identity and formulation of this catalogue vial have not been independently verified.
What do the selected Tirzepatide studies not establish?
Tirzepatide: SURMOUNT-1 (2022): Gastrointestinal events were common and some participants discontinued treatment because of adverse events. Results do not validate a research vial.
These studies do not establish the identity, purity, safety or effects of the MXC Tirzepatide vial. Findings in one formulation, population or experimental model should not be assumed to apply to another.